Biotest Aktiengesellschaft (BIESF)
USD 32.0
(11.19%)
USD 32.0
(11.19%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 381.9 Million EUR | -32.4% |
| 2022 | 564.9 Million EUR | 15.31% |
| 2021 | 489.9 Million EUR | 6.22% |
| 2020 | 461.2 Million EUR | 14.64% |
| 2019 | 402.3 Million EUR | 22.39% |
| 2018 | 328.7 Million EUR | 14.61% |
| 2017 | 286.8 Million EUR | -13.09% |
| 2016 | 330 Million EUR | -1.64% |
| 2015 | 335.5 Million EUR | 2.98% |
| 2014 | 325.8 Million EUR | 44.03% |
| 2013 | 226.2 Million EUR | 218.44% |
| 2012 | 71.03 Million EUR | -54.34% |
| 2011 | 155.58 Million EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| 2003 | - EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 429.7 Million EUR | -13.34% |
| 2024 Q1 | 429.5 Million EUR | 13.84% |
| 2023 Q2 | 589.8 Million EUR | -4.7% |
| 2023 Q3 | 652 Million EUR | 10.55% |
| 2023 FY | 381.9 Million EUR | -32.4% |
| 2023 Q4 | 381.9 Million EUR | -41.43% |
| 2023 Q1 | 618.9 Million EUR | 9.56% |
| 2022 FY | 564.9 Million EUR | 15.31% |
| 2022 Q3 | 504.2 Million EUR | 6.53% |
| 2022 Q2 | 473.3 Million EUR | -4.98% |
| 2022 Q4 | 564.9 Million EUR | 12.04% |
| 2022 Q1 | 498.1 Million EUR | 1.67% |
| 2021 Q1 | 463.7 Million EUR | 0.54% |
| 2021 FY | 489.9 Million EUR | 6.22% |
| 2021 Q2 | 489.59 Million EUR | 5.59% |
| 2021 Q3 | 496.3 Million EUR | 1.37% |
| 2021 Q4 | 489.9 Million EUR | -1.29% |
| 2020 Q2 | 459.2 Million EUR | 13.13% |
| 2020 Q1 | 405.9 Million EUR | 0.89% |
| 2020 Q3 | 460.6 Million EUR | 0.3% |
| 2020 Q4 | 461.2 Million EUR | 0.13% |
| 2020 FY | 461.2 Million EUR | 14.64% |
| 2019 Q2 | 52.3 Million EUR | -85.07% |
| 2019 FY | 402.3 Million EUR | 22.39% |
| 2019 Q4 | 402.3 Million EUR | -0.37% |
| 2019 Q3 | 403.8 Million EUR | 672.08% |
| 2019 Q1 | 350.3 Million EUR | 6.57% |
| 2018 FY | 328.7 Million EUR | 14.61% |
| 2018 Q4 | 328.7 Million EUR | 3.11% |
| 2018 Q2 | 360.7 Million EUR | 79.1% |
| 2018 Q1 | 201.4 Million EUR | -29.78% |
| 2018 Q3 | 318.8 Million EUR | -11.62% |
| 2017 Q3 | 388.5 Million EUR | -1.99% |
| 2017 Q2 | 396.4 Million EUR | 18.93% |
| 2017 Q4 | 286.8 Million EUR | -26.18% |
| 2017 Q1 | 333.3 Million EUR | 1.0% |
| 2017 FY | 286.8 Million EUR | -13.09% |
| 2016 Q1 | 339.5 Million EUR | 1.19% |
| 2016 Q3 | 330.6 Million EUR | -1.2% |
| 2016 FY | 330 Million EUR | -1.64% |
| 2016 Q4 | 330 Million EUR | -0.18% |
| 2016 Q2 | 334.6 Million EUR | -1.44% |
| 2015 Q3 | 336.4 Million EUR | -0.56% |
| 2015 FY | 335.5 Million EUR | 2.98% |
| 2015 Q4 | 335.5 Million EUR | -0.27% |
| 2015 Q2 | 338.3 Million EUR | 0.48% |
| 2015 Q1 | 336.7 Million EUR | 3.35% |
| 2014 Q2 | 241.1 Million EUR | 0.17% |
| 2014 Q3 | 241.8 Million EUR | 0.29% |
| 2014 Q4 | 325.8 Million EUR | 34.74% |
| 2014 FY | 325.8 Million EUR | 44.03% |
| 2014 Q1 | 240.7 Million EUR | 6.41% |
| 2013 Q3 | 68.2 Million EUR | -2.71% |
| 2013 Q4 | 226.2 Million EUR | 231.67% |
| 2013 FY | 226.2 Million EUR | 218.44% |
| 2013 Q1 | 62.6 Million EUR | -11.87% |
| 2013 Q2 | 70.1 Million EUR | 11.98% |
| 2012 FY | 71.03 Million EUR | -54.34% |
| 2012 Q3 | 152.1 Million EUR | -2.56% |
| 2012 Q4 | 71.03 Million EUR | -53.3% |
| 2012 Q1 | 152.5 Million EUR | -1.98% |
| 2012 Q2 | 156.1 Million EUR | 2.36% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q4 | 155.58 Million EUR | -14.7% |
| 2011 FY | 155.58 Million EUR | 0.0% |
| 2011 Q2 | 178.2 Million EUR | 0.0% |
| 2011 Q3 | 182.4 Million EUR | 2.36% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q3 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q1 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| 2003 FY | - EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ContraFect Corporation | 2.21 Million USD | -17180.543% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -166166.854% |
| Zenith Capital Corp. | 4456.00 USD | -8570366.786% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -20016.22% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -27121.523% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -21654.746% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -651139.726% |
| Qrons Inc. | 80 Thousand USD | -477275.0% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -302270.509% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -68761.682% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -6937.711% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -4521.249% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -30990.209% |
| CytoDyn Inc. | 141 Thousand USD | -270751.064% |
| Evofem Biosciences, Inc. | 8000.00 USD | -4773650.0% |
| IMV Inc. | 27.39 Million USD | -1293.868% |
| Genus plc | 228.2 Million USD | -67.353% |
| Halberd Corporation | 150 Thousand USD | -254500.0% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -57145.3% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -17056.334% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -255156.861% |
| Enzolytics Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 96.602% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -222933.347% |
| SQZ Biotechnologies Company | 20.9 Million USD | -1726.486% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -6928419.594% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -166456.908% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -127200.0% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -586.722% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 100.29 Million USD | -280.777% |
| MultiCell Technologies, Inc. | 36.43 USD | -1048311730.909% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | -129.915% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -118502.484% |
| argenx SE | 15.35 Million USD | -2387.3% |
| Resverlogix Corp. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -232475.135% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -1780.169% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -1509445.832% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| ONE Bio Corp. | 592.19 Thousand USD | -64388.566% |
| Genscript Biotech Corporation | 287.12 Million USD | -33.006% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -143668.705% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -35892757.143% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -255156.861% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -4783.657% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -103382.193% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 445 Thousand USD | -85720.225% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -4585.89% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -83466.74% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -32794.057% |
| PureTech Health plc | 18.25 Million USD | -1992.603% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -254500.0% |
| IXICO plc | 275 Thousand USD | -138772.727% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -3125.779% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -1351.595% |
| CSL Limited | 11.23 Billion USD | 96.602% |
| Cellectis S.A. | 36.21 Million USD | -954.648% |